Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trialThomas L Holland, Robert C. Hyzy, Thomas A. Murray et al.|The Lancet Respiratory Medicine|2022Cited by 127
Effect of P2Y12 Inhibitors on Organ Support–Free Survival in Critically Ill Patients Hospitalized for COVID-19Jeffrey S. Berger, Matthew D. Neal, Lucy Z. Kornblith et al.|JAMA Network Open|2023Cited by 17